Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer
Type of Study: Clinical Trial
Sponsor / Support: LACOG
Primary Objectives: To evaluate the efficacy, assessed by 12 weeks progression-free survival (PFS), of Palbociclib plus Letrozole in ER/PR positive serous ovarian cancer that progressed on second line chemotherapy.
Design: Multicenter, single arm, phase II clinical trial.
Sample Size: 39 patients
Principal Investigator: Fernanda Bronzon Damian
Countries LATAM: Brazil

Ongoing studies
Breast
GBECAM 0115 – AMAZONA III
LACOG 0115 – LORELEI
LACOG 0413 – Male Breast Cancer
LACOG 0615 – LATINABreast
LACOG 2118 – ALEXANDRA/IMpassion 030
PALLAS
Gastro-Intestinal
LACOG/GTG 1318 – CCA
LACOG 0119
Gynecological
LACOG 0215 – EVITA
LACOG 1018 – PALBO in Ovarian Cancer
Genitourinary
LACOG 1518 – Bladder Cancer Registry
LACOG 0515 – Testicular Registry
LACOG 0217 – IRONMAN
LACOG 1818 – Prostate Cancer Registry
LACOG 0218 – Hercules
LACOG 0415 – APA in Prostate Cancer
LACOG 0519 – PEACE III
Lung
LACOG 0116 – LATINO LUNG
LACOG 0118 – RELANCE
LACOG 0417 – CNS MTX
LACOG 1918
LACOG 0718 – PCI Project
LACOG 2218 – PACIFIC BRAZIL
Neuro
LACOG 0619